Erick Gamelin
Chief Development Officer · Acrivon Therapeutics, Inc.
- 2024
- Aug 20, 2026
- 9
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Erick Gamelin files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Peter Blume-Jensen - $117K in ACRV purchases and sales in the last 12 months
- Eric Devroe - $18K in ACRV purchases and sales in the last 12 months
- Adam D. Levy - $17K in ACRV purchases and sales in the last 12 months
- Mary Miller - $2K in ACRV purchases and sales in the last 12 months
- Katharine Peterson - $203 in ACRV purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Erick Gamelin?
Erick Gamelin is a corporate insider, tracked as Chief Development Officer of Acrivon Therapeutics, Inc. (ACRV). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Erick Gamelin submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Erick Gamelin been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($804) across all tracked filings.
